1
|
Hajji N, Garcia-Revilla J, Sarmiento Soto M, Perryman R, Symington JJ, Quarles CC, Healey DR, Guo Y, Orta-Vázquez ML, Mateos-Cordero S, Shah K, Bomalaski J, Anichini G, Tzakos AG, Crook T, O'Neill K, Scheck AC, Venero JL, Syed N. Arginine deprivation alters microglia polarity and synergises with radiation to eradicate non arginine auxotrophic glioblastoma tumors. J Clin Invest 2022; 132:142137. [PMID: 35113813 PMCID: PMC8920336 DOI: 10.1172/jci142137] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2020] [Accepted: 01/28/2022] [Indexed: 11/21/2022] Open
Abstract
New approaches for the management of glioblastoma (GBM) are an urgent and unmet clinical need. Here, we illustrate that the efficacy of radiotherapy for GBM is strikingly potentiated by concomitant therapy with the arginine-depleting agent ADI-PEG20 in a non-arginine-auxotrophic cellular background (argininosuccinate synthetase 1 positive). Moreover, this combination led to durable and complete radiological and pathological response, with extended disease-free survival in an orthotopic immune-competent model of GBM, with no significant toxicity. ADI-PEG20 not only enhanced the cellular sensitivity of argininosuccinate synthetase 1–positive GBM to ionizing radiation by elevated production of nitric oxide (˙NO) and hence generation of cytotoxic peroxynitrites, but also promoted glioma-associated macrophage/microglial infiltration into tumors and turned their classical antiinflammatory (protumor) phenotype into a proinflammatory (antitumor) phenotype. Our results provide an effective, well-tolerated, and simple strategy to improve GBM treatment that merits consideration for early evaluation in clinical trials.
Collapse
Affiliation(s)
- Nabil Hajji
- Department of Brain Sciences, Imperial College, London, United Kingdom
| | - Juan Garcia-Revilla
- Department of Biochemistry and Molecular Biology, University of Seville, Seville, Spain
| | - Manuel Sarmiento Soto
- Department of Biochemistry and Molecular Biology, University of Seville, Seville, Spain
| | - Richard Perryman
- Department of Brain Sciences, Imperial College, London, United Kingdom
| | - Jake J Symington
- Department of Brain Sciences, Imperial College, London, United Kingdom
| | - Chad C Quarles
- Division of Neuroimaging Research, Barrow Neurological Institute, Phoenix, United States of America
| | - Deborah R Healey
- Division of Neuroimaging Research, Barrow Neurological Institute, Phoenix, United States of America
| | - Yijie Guo
- Division of Neuroimaging Research, Barrow Neurological Institute, Phoenix, United States of America
| | | | | | - Khalid Shah
- Center for Stem Cell Therapeutics and Imaging (CSTI), Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America
| | - John Bomalaski
- Polaris, Polaris Pharmaceuticals, Inc., San Diego, United States of America
| | - Giulio Anichini
- Department of Brain Sciences, Imperial College, London, United Kingdom
| | - Andreas G Tzakos
- Department of Chemistry, University of Ioannina, Ioannina, Greece
| | - Timothy Crook
- Department of Brain Sciences, Imperial College, London, United Kingdom
| | - Kevin O'Neill
- Department of Brain Sciences, Imperial College, London, United Kingdom
| | - Adrienne C Scheck
- Department of Child Health, University of Arizona College of Medicine, Phoenix, United States of America
| | - Jose Luis Venero
- Department of Biochemistry and Molecular Biology, University of Seville, Seville, Spain
| | - Nelofer Syed
- Department of Brain Sciences, Imperial College, London, United Kingdom
| |
Collapse
|